SUPN (Supernus Pharmaceuticals, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by SUPN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-14 | Jonathan Rubin | SVP, Chief Medical Officer | MIXED | — | — |
| 2026-08-14 | Frank Mottola | SVP, Chief Tech. Ops. Officer | MIXED | — | — |
| 2026-08-14 | TIMOTHY C DEC | Senior Vice-President & CFO | MIXED | — | — |
| 2026-08-14 | Padmanabh P. Bhatt | Sr. VP of IP, CSO | MIXED | — | — |
| 2026-08-14 | Jack A. Khattar | President, CEO | MIXED | — | — |
| 2026-07-31 | Jonathan Rubin | SVP, Chief Medical Officer | A | — | — |
| 2026-07-31 | Jack A. Khattar | President, CEO | A | — | — |
| 2026-07-31 | TIMOTHY C DEC | Senior Vice-President & CFO | A | — | — |
| 2026-07-31 | Padmanabh P. Bhatt | Sr. VP of IP, CSO | A | — | — |
| 2026-07-31 | Frank Mottola | SVP, Chief Tech. Ops. Officer | A | — | — |
| 2026-03-18 | Padmanabh P. Bhatt | Sr. VP of IP, CSO | MIXED | — | — |
| 2026-03-16 | Frederick M. Hudson | Director | Sell | — | — |
| 2026-03-16 | Jack A. Khattar | President, CEO | MIXED | — | — |
| 2026-03-10 | TIMOTHY C DEC | Senior Vice-President & CFO | MIXED | — | — |
| 2026-03-10 | Frank Mottola | SVP, Chief Tech. Ops. Officer | MIXED | — | — |
| 2026-03-10 | Jack A. Khattar | President, CEO | MIXED | — | — |
| 2026-03-10 | William Todd Horich | SVP, Commercial Operations | MIXED | — | — |
| 2026-03-09 | GEORGES GEMAYEL | Director | MIXED | — | — |
| 2026-03-03 | Frank Mottola | SVP, Chief Tech. Ops. Officer | A | — | — |
| 2026-03-03 | Jack A. Khattar | President, CEO | A | — | — |
| 2026-03-03 | TIMOTHY C DEC | Senior Vice-President & CFO | A | — | — |
| 2026-02-26 | Jonathan Rubin | SVP, Chief Medical Officer | MIXED | — | — |
| 2026-02-26 | Padmanabh P. Bhatt | Sr. VP of IP, CSO | MIXED | — | — |
| 2026-02-26 | TIMOTHY C DEC | Senior Vice-President & CFO | MIXED | — | — |
| 2026-02-26 | Frank Mottola | SVP, Chief Tech. Ops. Officer | MIXED | — | — |
| 2026-02-25 | Frederick M. Hudson | Director | A | — | — |
| 2026-02-25 | GEORGES GEMAYEL | Director | MIXED | — | — |
| 2026-02-25 | CHARLES W NEWHALL III | Director | A | — | — |
| 2026-02-25 | Carrolee Barlow | Director | A | — | — |
| 2026-02-25 | TIMOTHY C DEC | Senior Vice-President & CFO | MIXED | — | — |
| 2026-02-25 | Padmanabh P. Bhatt | Sr. VP of IP, CSO | MIXED | — | — |
| 2026-02-25 | Jonathan Rubin | SVP, Chief Medical Officer | MIXED | — | — |
| 2026-02-25 | Frank Mottola | SVP, Chief Tech. Ops. Officer | MIXED | — | — |
| 2026-02-23 | Bethany Sensenig | Director | MIXED | — | — |
| 2026-02-20 | Jonathan Rubin | SVP, Chief Medical Officer | A | — | — |
| 2026-02-20 | Frank Mottola | SVP, Chief Tech. Ops. Officer | A | — | — |
| 2026-02-20 | CHARLES W NEWHALL III | Director | A | — | — |
| 2026-02-20 | TIMOTHY C DEC | Senior Vice-President & CFO | A | — | — |
| 2026-02-20 | Frederick M. Hudson | Director | A | — | — |
| 2026-02-20 | GEORGES GEMAYEL | Director | A | — | — |
| 2026-02-20 | Jack A. Khattar | President, CEO | A | — | — |
| 2026-02-20 | Carrolee Barlow | Director | A | — | — |
| 2026-02-20 | Bethany Sensenig | Director | A | — | — |
| 2026-02-20 | Padmanabh P. Bhatt | Sr. VP of IP, CSO | A | — | — |
| 2026-01-12 | Frederick M. Hudson | Director | M | — | — |
| 2025-12-22 | Frank Mottola | SVP, Chief Tech. Ops. Officer | MIXED | — | — |
| 2025-12-19 | Padmanabh P. Bhatt | Sr. VP of IP, CSO | MIXED | — | — |
| 2025-11-24 | CHARLES W NEWHALL III | Director | M | — | — |
| 2025-11-17 | Padmanabh P. Bhatt | Sr. VP of IP, CSO | A | — | — |
| 2025-10-10 | CHARLES W NEWHALL III | Director | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 6,365,369 | — |
| — | 10%+ Owner | 6,241,250 | — |
| — | 10%+ Owner | 4,993,557 | — |
| — | 10%+ Owner | 3,820,625 | — |
| — | 10%+ Owner | 3,600,000 | — |
| — | President, CEO | 2,229,093 | — |
| — | 10%+ Owner | 858,100 | — |
| — | Director | 624,710 | — |
| — | Director | 297,815 | — |
| — | Director | 130,715 | — |
| — | Director | 87,943 | — |
| — | Sr. V.P., Regulatory Affairs | 86,933 | — |
| — | 10%+ Owner | 71,749 | — |
| — | VP of Business Development | 67,980 | — |
| — | Director | 60,413 | — |
| — | Executive Vice President & CMO | 49,119 | — |
| — | Sr. VP Chief Financial Officer | 44,463 | — |
| — | Director | 28,159 | — |
| — | Director | 27,045 | — |
| — | Director | 23,750 | — |
| — | Sr. VP of IP, CSO | 19,795 | — |
| — | SVP, Chief Tech. Ops. Officer | 19,544 | — |
| — | SVP, Chief Medical Officer | 14,342 | — |
| — | Sr. VP of Sales & Marketing | 9,344 | — |
| — | Senior Vice-President & CFO | 9,129 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SUPN quote page; the site-wide leaderboard is on the insider transactions hub.